BUSINESS
Ultragenyx to Ramp Up Ultra-Orphan Drug Development, Bolster Hiring in Japan
Ultragenyx Pharmaceutical aims to lay the groundwork for growth in the Japan market with its recently launched Mepsevii (vestronidase alfa) and forge ahead with the rollout of another ultra-orphan drug evinacumab in 2024. The company hopes to bring all nine…
To read the full story
Related Article
- Ultragenyx Plans Japan Submission of Evinacumab in May: CEO
March 31, 2023
BUSINESS
- PMP Returns Slam Drug Makers' Leading Products, Prazaxa Cut 45%: Jiho Poll
March 13, 2026
- Lilly to Invest Additional 20 Billion Yen in Japan's Seishin Plant
March 13, 2026
- Fujifilm Invests in Austria’s Valanx Biotech to Boost ADC Technology
March 13, 2026
- Merck, CDMO Cyto-Facto Join Hands on Cell and Gene Therapy
March 13, 2026
- Anti-PD-1 Agonist Antibody Enters PI in Australia for Autoimmune Diseases: Meiji
March 13, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





